Stock-Based Compensation for Biogen (BIIB)
Stock-Based Compensation for Biogen (BIIB): headline value $231.20M · YoY -0.1%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
BIIB
Currently viewingStock-Based CompensationSwitch metric
Latest period
$231.20M
YoY change
-0.1%
5Y CAGR
+8.0%
Peak year (2024)
$291.20M
Latest annual
$290.80M
Stock-Based Compensation history chart for Biogen (BIIB) from 1989 to 2025
Stock-Based Compensation history table for Biogen (BIIB) from 1989 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $290.80M | -0.1% | ||
| 2024 | $291.20M | +10.2% | ||
| 2023 | $264.20M | +4.0% | ||
| 2022 | $254.10M | +6.5% | ||
| 2021 | $238.60M | +20.3% | ||
| 2020 | $198.30M | +8.8% | ||
| 2019 | $182.30M | +15.7% | ||
| 2018 | $157.50M | +23.0% | ||
| 2017 | $128.00M | -17.3% | ||
| 2016 | $154.80M | -4.1% | ||
| 2015 | $161.40M | +3.9% | ||
| 2014 | $155.30M | +13.9% | ||
| 2013 | $136.29M | +15.0% | ||
| 2012 | $118.57M | +4.9% | ||
| 2011 | $113.00M | -32.7% | ||
| 2010 | $167.83M | +4.3% | ||
| 2009 | $160.90M | +10.1% | ||
| 2008 | $146.21M | +18.7% | ||
| 2007 | $123.13M | -2.9% | ||
| 2006 | $126.78M | +232.4% | ||
| 2005 | $38.15M | +127.1% | ||
| 2004 | $16.80M | — | ||
| 2003 | $0 | -100.0% | ||
| 2002 | $2.36M | — | ||
| 2001 | $0 | — | ||
| 2000 | $0 | — | ||
| 1999 | $0 | — | ||
| 1998 | $0 | — | ||
| 1997 | $0 | — | ||
| 1996 | $0 | — | ||
| 1995 | $0 | — | ||
| 1994 | $0 | — | ||
| 1993 | $0 | — | ||
| 1992 | $0 | — | ||
| 1991 | $0 | — | ||
| 1990 | $0 | — | ||
| 1989 | $0 | — |
Stock-Based Compensation values are taken from Biogen's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
2025's annual stock-based compensation for Biogen (BIIB) came in at $290.80M – edged down 0.1% year-over-year.
Across 2020–2025 (5 years), Biogen stock-based compensation produced a CAGR of +8.0% – with the latest reading among the more recent periods of the dataset.
2024 marks the peak stock-based compensation at $291.20M, with the historical low of $0 recorded in 1989.
Among 8 Healthcare peers, Biogen (BIIB) ranks 5th; the peer median for stock-based compensation is $313.00M.
Biogen Stock-Based Compensation by Year
Biogen Stock-Based Compensation 2025: $290.80M
Biogen stock-based compensation in 2025 was $290.80M, edged down 0.1% below 2024.
Biogen Stock-Based Compensation 2024: $291.20M
Biogen stock-based compensation in 2024 was $291.20M, grew 10.2% from 2023. This figure represents the highest annual value in the available history.
Biogen Stock-Based Compensation 2023: $264.20M
Biogen stock-based compensation in 2023 was $264.20M, edged up 4.0% from 2022.
Biogen Stock-Based Compensation 2022: $254.10M
Biogen stock-based compensation in 2022 was $254.10M, grew 6.5% from 2021.
Biogen Stock-Based Compensation 2021: $238.60M
Biogen stock-based compensation in 2021 was $238.60M.
See more financial history for Biogen (BIIB).
Sector peers — Stock-Based Compensation
Companies in the same sector as Biogen, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Biogen's stock-based compensation?
Latest reported stock-based compensation for Biogen (BIIB) is $231.20M (period ending December 31, 2025).
How has Biogen stock-based compensation changed year-over-year?
Biogen (BIIB) stock-based compensation changed -0.1% year-over-year on the latest annual filing.
What is the long-term growth rate of Biogen stock-based compensation?
Biogen (BIIB) stock-based compensation compound annual growth rate is +8.0% over the most recent 5 years available.
When did Biogen stock-based compensation hit its highest annual value?
Biogen stock-based compensation reached its highest annual value of $291.20M in 2024.
What was Biogen stock-based compensation in 2024?
Biogen (BIIB) stock-based compensation in 2024 was $291.20M.
What was Biogen stock-based compensation in 2025?
Biogen (BIIB) stock-based compensation in 2025 was $290.80M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
BIIB Overview
Company profile, financial tools, and key metrics
BIIB Revenue Counter
Earns $311.09 every second. See per minute, hour, and day.
BIIB Earnings Counter
Earns $41.01 per second net profit. See per minute, hour, and day.
BIIB Economic Scale
Exceeds Bermuda's GDP. Compare with world economies.
BIIB What If Invested
What if you had invested $1,000? See historical returns from any date.
BIIB How It Makes Money
Discover visual breakdown of $9.81B in revenue — where it comes from and where it goes.
BIIB Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
BIIB Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
BIIB Daily Price Character
Explosive · 48.1% historical win rate (green days). Streaks & record days.
BIIB Buybacks
Recent repurchase activity. Shareholder yield & SBC comparison.
BIIB Stock Split History
2 splits on record. Dates, ratios, and cumulative multiple.